UCT-03-008 for Solid Tumors

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Torrance Memorial, Torrance, CASolid TumorsUCT-03-008 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study a new drug to see if it is safe and effective in treating patients with advanced solid tumors.

Eligible Conditions
  • Advanced Solid Tumors

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
BTRC4017A
1
TORL-1-23
1
Ami-LC

Study Objectives

3 Primary · 17 Secondary · Reporting Duration: 2 years

1 year
1 Year Overall Survival (1YOS)
2 years
2 Year Overall Survival (2YOS)
28 Days
Maximum Tolerated Dose (MTD)
Day 28
Apparent Clearance (CL/F) of UCT-03-008
Apparent Volume of Distribution (Vz/F) of UCT-03-008
Area Under the Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) of UCT-03-008
Area Under the Plasma Concentration-Time Curve from the time of dosing to the last measurable concentration (AUClast) of UCT-03-008
Minimum Plasma UCT-03-008 Concentration following single dose (Cmin)
Time of Maximum Plasma UCT-03-008 Concentration at steady state (Tmax,ss)
Time of Maximum Plasma UCT-03-008 Concentration following single dose (Tmax)
Day 28
Maximum Plasma UCT-03-008 Concentration following single dose (Cmax)
Day 28
Maximum Plasma UCT-03-008 Concentration at steady state (Cmax,ss)
Minimum Plasma UCT-03-008 Concentration at steady state (Cmin,ss)
Terminal Half-life (t1/2) of plasma UCT-03-008
up to 2 years
Duration of Response (DOR)
Incidence and severity of adverse events and serious adverse events
Objective Response Rate (ORR)
Progression Free Survival (PFS)
Recommended Phase 2 Dose (RP2D)
Time to Response (TTR)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
BTRC4017A
1
TORL-1-23
1
Ami-LC

Trial Design

2 Treatment Groups

Dose Finding as Monotherapy - Part 1
1 of 2
Expansion as Monotherapy - Part 2
1 of 2

Experimental Treatment

68 Total Participants · 2 Treatment Groups

Primary Treatment: UCT-03-008 · No Placebo Group · Phase 1

Dose Finding as Monotherapy - Part 1
Drug
Experimental Group · 1 Intervention: UCT-03-008 · Intervention Types: Drug
Expansion as Monotherapy - Part 2
Drug
Experimental Group · 1 Intervention: UCT-03-008 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

1200 Pharma, LLCLead Sponsor
1 Previous Clinical Trials
106 Total Patients Enrolled
Translational Research in OncologyOTHER
19 Previous Clinical Trials
6,791 Total Patients Enrolled
Stephen Letrent, PharmD, PhDStudy Director1200 Pharma, LLC
4 Previous Clinical Trials
336 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have an advanced form of cancer that has spread beyond its original location.
References

Frequently Asked Questions

To what degree does UCT-03-008 endanger humans?

"Because of the limited data on safety and efficacy, UCT-03-008 was rated a 1 by our team at Power." - Anonymous Online Contributor

Unverified Answer

What aims are being pursued with this research endeavor?

"Over the course of two years, this trial seeks to identify a Recommended Phase 2 Dose (RP2D). Additional objectives include ascertaining Minimum Plasma UCT-03-008 Concentration at steady state (Cmin,ss), determining Time to Response (TTR) from start of treatment until either complete or partial response is achieved, and assessing Maximum Plasma UCT-03-008 Concentration at steady state (Cmax,ss)." - Anonymous Online Contributor

Unverified Answer

What is the maximum capacity of this research study?

"Affirmative. According to the clinicaltrials.gov webpage, this project is actively seeking participants and needs 68 people from 3 different sites. The trial was first made public on December 23rd 2021 and its information has been updated as recently as July 25th 2022." - Anonymous Online Contributor

Unverified Answer

Is enrollment currently available for this trial?

"Affirmative. According to clinicaltrials.gov, this medical study is actively looking for participants and was first published on December 23rd 2021 with the latest update occurring July 25th 2022. The research team seeks 68 individuals across 3 locations." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top